Fermenta Biotech Limited (BOM:506414)
311.30
-13.65 (-4.20%)
At close: Jan 23, 2026
Fermenta Biotech Revenue
Fermenta Biotech had revenue of 1.30B INR in the quarter ending September 30, 2025, with 37.04% growth. This brings the company's revenue in the last twelve months to 5.63B, up 52.33% year-over-year. In the fiscal year ending March 31, 2025, Fermenta Biotech had annual revenue of 4.69B with 39.87% growth.
Revenue (ttm)
5.63B
Revenue Growth
+52.33%
P/S Ratio
1.63
Revenue / Employee
9.29M
Employees
606
Market Cap
9.16B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 4.69B | 1.34B | 39.87% |
| Mar 31, 2024 | 3.36B | -142.79M | -4.08% |
| Mar 31, 2023 | 3.50B | -485.75M | -12.19% |
| Mar 31, 2022 | 3.99B | 212.27M | 5.63% |
| Mar 31, 2021 | 3.77B | 843.40M | 28.79% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| TTK Healthcare | 8.25B |
| Anuh Pharma | 7.30B |
| Venus Remedies | 6.99B |
| Lincoln Pharmaceuticals | 6.32B |
| Wanbury | 6.31B |
| Kopran | 5.92B |
| Fredun Pharmaceuticals | 5.31B |
| Syncom Formulations (India) | 5.15B |